Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical case

The combination of lenvatinib and pembrolizumab has emerged as the first non-chemo treatment for advanced endometrial cancer, particularly in cases refractory to standard therapies. This case describes the efficacy and safety of the combination of lenvatinib and pembrolizumab in the treatment of a 6...

Full description

Saved in:
Bibliographic Details
Main Authors: E. A. Khachaturyan, T. G. Antonova, O. A. Stativko, I. A. Pokataev
Format: Article
Language:Russian
Published: ABV-press 2025-05-01
Series:Опухоли женской репродуктивной системы
Subjects:
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/1356
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849399027894845440
author E. A. Khachaturyan
T. G. Antonova
O. A. Stativko
I. A. Pokataev
author_facet E. A. Khachaturyan
T. G. Antonova
O. A. Stativko
I. A. Pokataev
author_sort E. A. Khachaturyan
collection DOAJ
description The combination of lenvatinib and pembrolizumab has emerged as the first non-chemo treatment for advanced endometrial cancer, particularly in cases refractory to standard therapies. This case describes the efficacy and safety of the combination of lenvatinib and pembrolizumab in the treatment of a 62-year-old patient with endometrioid adenocarcinoma who received first-line therapy with the combination of lenvatinib and pembrolizumab in the absence of repair system deficiency after adjuvant therapy. This combination offers the potential to extend survival in patients with mismatch repair proficient endometrial cancer who have received systemic neoadjuvant or adjuvant therapy.
format Article
id doaj-art-9a71ad1b5d2c455ab1daea46d077adc2
institution Kabale University
issn 1994-4098
1999-8627
language Russian
publishDate 2025-05-01
publisher ABV-press
record_format Article
series Опухоли женской репродуктивной системы
spelling doaj-art-9a71ad1b5d2c455ab1daea46d077adc22025-08-20T03:38:26ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272025-05-0121114214610.17650/1994-4098-2025-21-1-142-146903Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical caseE. A. Khachaturyan0T. G. Antonova1O. A. Stativko2I. A. Pokataev3Oncology Center No. 1, S. S. Yudin City Clinical Hospital, Moscow Healthcare DepartmentOncology Center No. 1, S. S. Yudin City Clinical Hospital, Moscow Healthcare DepartmentOncology Center No. 1, S. S. Yudin City Clinical Hospital, Moscow Healthcare DepartmentOncology Center No. 1, S. S. Yudin City Clinical Hospital, Moscow Healthcare DepartmentThe combination of lenvatinib and pembrolizumab has emerged as the first non-chemo treatment for advanced endometrial cancer, particularly in cases refractory to standard therapies. This case describes the efficacy and safety of the combination of lenvatinib and pembrolizumab in the treatment of a 62-year-old patient with endometrioid adenocarcinoma who received first-line therapy with the combination of lenvatinib and pembrolizumab in the absence of repair system deficiency after adjuvant therapy. This combination offers the potential to extend survival in patients with mismatch repair proficient endometrial cancer who have received systemic neoadjuvant or adjuvant therapy.https://ojrs.abvpress.ru/ojrs/article/view/1356targeted therapypembrolizumablenvatinibendometrial cancerroutine clinical practice
spellingShingle E. A. Khachaturyan
T. G. Antonova
O. A. Stativko
I. A. Pokataev
Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical case
Опухоли женской репродуктивной системы
targeted therapy
pembrolizumab
lenvatinib
endometrial cancer
routine clinical practice
title Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical case
title_full Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical case
title_fullStr Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical case
title_full_unstemmed Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical case
title_short Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical case
title_sort lenvatinib in combination with pembrolizumab as first line therapy for advanced endometrial cancer clinical case
topic targeted therapy
pembrolizumab
lenvatinib
endometrial cancer
routine clinical practice
url https://ojrs.abvpress.ru/ojrs/article/view/1356
work_keys_str_mv AT eakhachaturyan lenvatinibincombinationwithpembrolizumabasfirstlinetherapyforadvancedendometrialcancerclinicalcase
AT tgantonova lenvatinibincombinationwithpembrolizumabasfirstlinetherapyforadvancedendometrialcancerclinicalcase
AT oastativko lenvatinibincombinationwithpembrolizumabasfirstlinetherapyforadvancedendometrialcancerclinicalcase
AT iapokataev lenvatinibincombinationwithpembrolizumabasfirstlinetherapyforadvancedendometrialcancerclinicalcase